What is Zacks Research’s Forecast for Stryker Q2 Earnings?

Stryker Co. (NYSE:SYK) – Equities researchers at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Stryker in a research report issued to clients and investors on Thursday, May 22nd. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical technology company will post earnings of $3.06 per share for the quarter, down from their prior forecast of $3.15. The consensus estimate for Stryker’s current full-year earnings is $13.47 per share. Zacks Research also issued estimates for Stryker’s Q3 2025 earnings at $3.13 EPS, FY2025 earnings at $13.29 EPS, Q1 2026 earnings at $3.05 EPS, Q2 2026 earnings at $3.28 EPS, Q3 2026 earnings at $3.28 EPS, Q4 2026 earnings at $4.78 EPS, Q1 2027 earnings at $3.92 EPS and FY2027 earnings at $16.55 EPS.

A number of other equities research analysts also recently issued reports on the company. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. BTIG Research set a $403.00 price target on Stryker and gave the company a “buy” rating in a research report on Monday, April 14th. Roth Mkm boosted their price target on Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Finally, Evercore ISI lowered their price target on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $427.30.

Stryker Price Performance

Shares of NYSE:SYK opened at $377.01 on Monday. The company has a market cap of $143.90 billion, a P/E ratio of 48.58, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker has a 52 week low of $314.93 and a 52 week high of $406.19. The business has a fifty day simple moving average of $368.06 and a 200-day simple moving average of $376.14.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.50 earnings per share.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio is currently 45.41%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. Norges Bank purchased a new position in Stryker in the fourth quarter valued at about $1,710,744,000. GAMMA Investing LLC raised its stake in Stryker by 43,226.8% during the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock valued at $772,390,000 after buying an additional 2,070,133 shares in the last quarter. Nuveen LLC acquired a new stake in Stryker during the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD raised its stake in Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Stryker during the fourth quarter valued at approximately $353,394,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.